User:Mr. Ibrahem/Tolvaptan
Clinical data | |
---|---|
Trade names | Samsca, Jinarc, Jynarque, others |
Other names | OPC-41061 |
AHFS/Drugs.com | Monograph |
MedlinePlus | a609033 |
License data | |
Pregnancy category |
|
Routes of administration | By mouth |
Drug class | Vasopressin-2 receptor (V2) antagonist[1] |
Legal status | |
Legal status | |
Pharmacokinetic data | |
Bioavailability | Unknown (40% absorbed) |
Protein binding | 99% |
Metabolism | Liver (CYP3A4-mediated)[7] |
Elimination half-life | 12 hours (terminal) |
Identifiers | |
| |
Chemical and physical data | |
Formula | C26H25ClN2O3 |
Molar mass | 448.95 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) (verify) |
Tolvaptan, sold under the brand name Samsca among others, is a medication used to treat low sodium due to heart failure or syndrome of inappropriate antidiuretic hormone (SIADH).[8] It is also used for autosomal dominant polycystic kidney disease (ADPKD).[9] It is taken by mouth.[9] Effects begin within 4 hours.[8]
Common side effects include thirst, nausea, and rapid increase in sodium.[1] Other complications may include osmotic demyelination syndrome, liver failure, and high potassium.[8] It is a vasopressin-2 receptor (V2) antagonist which works by increasing urine production.[1]
Tolvaptan was approved for medical use in the United States and Europe in 2009.[1][8] A generic version was approved in 2020, though was not available commercially as of 2021.[10] In the United States 10 tablets of 30 mg costs about 3,800 USD as of 2021.[11] This amount in the United Kingdom costs the NHS about £750.[9]
References[edit]
- ^ a b c d e f "Samsca EPAR". European Medicines Agency (EMA). Archived from the original on 6 January 2021. Retrieved 14 December 2020.
- ^ "Samsca 15 mg tablets - Summary of Product Characteristics (SmPC)". (emc). Archived from the original on 24 January 2021. Retrieved 14 December 2020.
- ^ "Jinarc 15 mg tablets - Summary of Product Characteristics (SmPC)". (emc). 21 April 2020. Archived from the original on 17 January 2021. Retrieved 14 December 2020.
- ^ "Jynarque- tolvaptan kit Jynarque- tolvaptan tablet". DailyMed. 31 March 2020. Archived from the original on 19 October 2020. Retrieved 14 December 2020.
- ^ "Samsca- tolvaptan tablet". DailyMed. 26 October 2020. Archived from the original on 18 January 2021. Retrieved 14 December 2020.
- ^ "Jinarc EPAR". European Medicines Agency (EMA). Archived from the original on 7 January 2021. Retrieved 14 December 2020.
- ^ Shoaf S, Elizari M, Wang Z, et al. (2005). "Tolvaptan administration does not affect steady state amiodarone concentrations in patients with cardiac arrhythmias". J Cardiovasc Pharmacol Ther. 10 (3): 165–71. doi:10.1177/107424840501000304. PMID 16211205. S2CID 39158242.
- ^ a b c d e f "Tolvaptan Monograph for Professionals". Drugs.com. Archived from the original on 17 August 2019. Retrieved 8 October 2021.
- ^ a b c d BNF (80 ed.). BMJ Group and the Pharmaceutical Press. September 2020 – March 2021. p. 706. ISBN 978-0-85711-369-6.
{{cite book}}
: CS1 maint: date format (link) - ^ "Drugs@FDA: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 20 October 2020. Retrieved 15 August 2020.
- ^ "Tolvaptan Prices, Coupons & Patient Assistance Programs". Drugs.com. Retrieved 8 October 2021.